Literature DB >> 9159722

Unchanged basal ganglia N-acetylaspartate and glutamate in idiopathic Parkinson's disease measured by proton magnetic resonance spectroscopy.

C E Clarke1, M Lowry, A Horsman.   

Abstract

The lentiform nucleus of five patients with idiopathic Parkinson's disease (IPD) was studied by quantitative magnetic resonance spectroscopy (MRS), both before and after administration of apomorphine, and the spectra were compared with those from a group of age-matched normal subjects. The concentrations of the three major metabolites, choline, creatine, and N-acetylaspartate (NAA), were quantified using tissue water content as an internal concentration reference. Glutamate concentration was assessed as the (glutamate + glutamine; GLX)/creatine peak area ratio. In normal subjects, the mean +/- SD concentrations of the the three metabolites were 2.4 +/- 0.4 mumol/g wet wt for choline, 11.5 +/- 0.8 mumol/g for creatine, and 14.7 +/- 2.8 mumol/g for NAA. The Glx/creatine ratio was 1.26 +/- 0.12. There was no significant difference in these parameters in the lentiform nucleus of patients with IPD either before or after apomorphine. The absence of detectable differences in IPD in this study implies that the changes in glutamate metabolism in the basal ganglia predicted by animal work are more subtle than those currently observable by MRS.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9159722     DOI: 10.1002/mds.870120306

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  14 in total

Review 1.  Magnetic resonance imaging and magnetic resonance spectroscopy in dementias.

Authors:  Y Y Hsu; A T Du; N Schuff; M W Weiner
Journal:  J Geriatr Psychiatry Neurol       Date:  2001       Impact factor: 2.680

2.  A proton magnetic resonance spectroscopy study of the striatum and cerebral cortex in Parkinson's disease.

Authors:  S D Taylor-Robinson; N Turjanski; S Bhattacharya; J P Seery; J Sargentoni; D J Brooks; D J Bryant; I J Cox
Journal:  Metab Brain Dis       Date:  1999-03       Impact factor: 3.584

3.  Evidence for cortical dysfunction in clinically non-demented patients with Parkinson's disease: a proton MR spectroscopy study.

Authors:  M T Hu; S D Taylor-Robinson; K R Chaudhuri; J D Bell; R G Morris; C Clough; D J Brooks; N Turjanski
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-07       Impact factor: 10.154

4.  Reduction of N-acetylaspartate in the medial prefrontal cortex correlated with symptom severity in obsessive-compulsive disorder: meta-analyses of (1)H-MRS studies.

Authors:  Yuta Aoki; Ai Aoki; Hiroshi Suwa
Journal:  Transl Psychiatry       Date:  2012-08-14       Impact factor: 6.222

Review 5.  MR spectroscopy in neurodegenerative disease.

Authors:  W R Wayne Martin
Journal:  Mol Imaging Biol       Date:  2007 Jul-Aug       Impact factor: 3.484

Review 6.  Candidate Biomarkers in Children with Autism Spectrum Disorder: A Review of MRI Studies.

Authors:  Dongyun Li; Hans-Otto Karnath; Xiu Xu
Journal:  Neurosci Bull       Date:  2017-03-10       Impact factor: 5.203

7.  Metabolic alterations in Parkinson's disease after thalamotomy, as revealed by 1H MR spectroscopy.

Authors:  Hyun-Man Baik; Bo-Young Choe; Hyoung-Koo Lee; Tae-Suk Suh; Byung-Chul Son; Jae-Mun Lee
Journal:  Korean J Radiol       Date:  2002 Jul-Sep       Impact factor: 3.500

8.  Absence of age-related prefrontal NAA change in adults with autism spectrum disorders.

Authors:  Y Aoki; O Abe; N Yahata; H Kuwabara; T Natsubori; N Iwashiro; Y Takano; H Inoue; Y Kawakubo; W Gonoi; H Sasaki; M Murakami; M Katsura; Y Nippashi; H Takao; A Kunimatsu; H Matsuzaki; K J Tsuchiya; N Kato; K Kasai; H Yamasue
Journal:  Transl Psychiatry       Date:  2012-10-23       Impact factor: 6.222

9.  Age-related change in brain metabolite abnormalities in autism: a meta-analysis of proton magnetic resonance spectroscopy studies.

Authors:  Y Aoki; K Kasai; H Yamasue
Journal:  Transl Psychiatry       Date:  2012-01-17       Impact factor: 6.222

Review 10.  Magnetic resonance spectroscopy: an in vivo molecular imaging biomarker for Parkinson's disease?

Authors:  Rosella Ciurleo; Giuseppe Di Lorenzo; Placido Bramanti; Silvia Marino
Journal:  Biomed Res Int       Date:  2014-09-11       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.